A Methodology for Assessing Tumor Clonality of Adult T Cell Leukemia/Lymphoma by Yamakawa Tomohiro et al.
Original ArticleA Methodology for Assessing Tumor
Clonality of Adult T Cell Leukemia/Lymphoma
Tomohiro Yamakawa,1 Naoki Uno,1 Daisuke Sasaki,1 Norihito Kaku,1 Kei Sakamoto,1 Kosuke Kosai,1
Hiroo Hasegawa,1 Yasushi Miyazaki,2 and Katsunori Yanagihara1
1Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan; 2Department of Hematology, Atomic Bomb
Disease and Hibakusya Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, JapanReceived 22 July 2020; accepted 17 October 2020;
https://doi.org/10.1016/j.omtm.2020.10.015.
Correspondence: Naoki Uno, Department of Laboratory Medicine, Nagasaki
University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-
8501, Japan.
E-mail: nuno@nagasaki-u.ac.jpWhile clonal heterogeneity has been demonstrated inmost can-
cers, quantitative assessment of individual tumor clones has
not been translated to inform clinical practice. A few methods
have been developed to investigate the tumor clonality of adult
T cell leukemia/lymphoma (ATLL), but currently there is no
clinically translatable method available for quantifying individ-
ual tumor clones in ATLL patients. Here, we present a method-
ology to assess the tumor clonality of ATLL and quantify pa-
tient-specific tumor clones in a clinical setting. The
methodology consists of three steps: (1) selective amplification
of restriction fragments containing a human T cell leukemia vi-
rus type 1 (HTLV-1) integration site, (2) amplicon deep
sequencing to estimate the clonal structure and identify
HTLV-1 integration sites of dominant clones, and (3) digital
PCR targeting the HTLV-1 integration sites of the dominant
clones to quantify specific tumor clones. We successfully
tracked individual tumor clones using this approach and
demonstrated that each clone had a distinct response to thera-
pies. The procedure is straightforward and clinically feasible,
which should facilitate the proper assessment and management
of ATLL.
INTRODUCTION
Recent advances in sequencing technologies have uncovered tumor
heterogeneity in most cancers.1 Distinct subpopulations of tumor
cells display remarkable variability in response to treatments.2
Increasing evidence of functional diversity between tumor subpopu-
lations suggests the need for assessing clonal heterogeneity in clinical
practice.1,3 However, inference of tumor composition using DNA
sequencing data is challenging4 and clinically applicable methods
for assessing individual tumor clones have yet to be developed.
Adult T cell leukemia/lymphoma (ATLL) is a hematological malig-
nancy caused by clonal proliferation of CD4+ T cells infected with
human T cell leukemia virus type 1 (HTLV-1). Following HTLV-
1 infection, viral DNA is synthesized from viral RNA by viral
reverse transcriptase and integrated into the human genome. The
integrated viral DNA is called a provirus. Each infected cell contains
a unique integration site (UIS) because integration occurs
throughout in the human genome,5 and the majority of CD4+
T cells from peripheral blood of HTLV-1-infected individualsMolecular Therapy: Methods & Clinic
This is an open access article under tcontain a single copy of a provirus.6 Therefore, an infected cell line-
age, which refers to an ancestral infected cell and its descendants,
can be identified by a UIS. Most individuals infected with HTLV-
1 are asymptomatic and never develop ATLL. However, in approx-
imately 5% of asymptomatic HTLV-1 carriers, infected cells prolif-
erate clonally and cause ATLL after a latency period of several de-
cades.7 The clonality of ATLL can be determined based on the UIS
because when an ancestral infected cell proliferates clonally and
gives rise to tumor cells, the UIS of the infected cell lineage becomes
the signature of that tumor clone. While gene rearrangements of
T cell receptor and immunoglobulins have been used to define
the clonality of lymphoproliferative neoplasms, UISs remain the
standard target for clonality detection in ATLL because tumor cells
only arise from T cells infected with HTLV-1.
Although UISs can be determined by whole-genome sequencing
(WGS),5 a few groups have developed methods to identify UISs by
amplicon deep sequencing and then used these UISs to analyze the
clonality of ATLL.8–10 One group reported that, in 89% of cases,
ATLL arose from a single ancestral infected cell, while in 11%, it arose
from two.11 These methods are based on enrichment of provirus-con-
taining sonicated DNA fragments prior to sequencing.8–10 While
such methods are able to reveal the tumor clonality of ATLL without
WGS, they are not feasible in a clinical setting because both the
sequencing data analysis and the experimental procedures are very
demanding. A previous study reported a simple method based on
the amplification of UISs in restriction-enzyme-digested genomic
DNA to investigate the clonality of HTLV-1-infected individuals,12
but has not been developed for clinical use.
Assessment of individual tumor clones helps physicians make appro-
priate disease assessments and decide on the optimal therapy.13 Here-
in, we present a clinically practical methodology for identifying and
evaluating individual tumor clones in ATLL patients.al Development Vol. 19 December 2020 ª 2020 The Author(s). 467
he CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Schematic of Amplification of Restriction
Fragments that Contain a HTLV-1 Integration Site
(A) The size of restriction fragments that contain both
provirus and human sequences is unique to each infected
cell. (B) The fragment containing the 30 LTR of a provirus
and human sequences was amplified by semi-nested
PCR. Following fragmentation of genomic DNA by a re-
striction enzyme, adaptors were ligated to the restriction
fragments and subsequently cleaved. The first round PCR
was performed using forward and reverse primers that
bind to the 30 LTR of a provirus (red) and an adaptor
sequence (yellow), respectively. The second PCR was
performed using a different primer set. The forward primer
used in the second PCR was designed to bind slightly
inside of the binding site of the first forward primer. The
binding sites of the reverse primers used in the first and
second PCR overlap at their 30 ends. Both forward and
reverse primers used in the second PCR have 50 se-
quences added for the downstream sequencing analysis.
Oligonucleotide sequences used for the semi-nested
PCR are shown in Table S2. The products were analyzed
by electrophoresis and deep sequencing.
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Experimental Design for Selective Amplification of Restriction
Fragments Containing HTLV-1 Provirus
We designed the experiments to investigate HTLV-1-infected cell lin-
eages based on UISs. A DNA library was prepared using a restriction
enzyme instead of sonication, because the size of restriction fragments
containing both provirus and human sequences is unique to each in-
fected cell lineage (Figure 1A). HpyCH4V was selected as the restric-
tion enzyme because the fragments it generates from digestion of the
human genome would be expected to be short enough to be amplified
by PCR. Following DNA fragmentation, we amplified fragments thatFigure 2. Clonal Proliferation of HTLV-1-Infected Cells Can Be Detected by
Agarose Gel Electrophoresis
Genomic DNA was extracted from PBMCs from asymptomatic HTLV-1 carriers (n =
8), ATLL patients (n = 10), and a healthy individual, or for ATLL case 4 from a lymph
node sample, and digested with HpyCH4V. Restriction fragments containing both
the 30 LTR of a provirus and human sequences were amplified as depicted in Fig-
ure 1B and analyzed by agarose gel electrophoresis.
468 Molecular Therapy: Methods & Clinical Development Vol. 19 Decemcontained a HTLV-1 integration site by semi-nested PCR. Specif-
ically, we ligated adaptors to restriction fragments using a DNA li-
brary preparation kit and used the fragment library as the template
for PCR. The PCR was performed to amplify fragments that con-
tained a UIS next to the provirus 30 long terminal repeat (LTR), which
is well conserved, whereas the 50 LTR is often truncated.14 We carried
out PCR using a forward primer binding to the provirus 30 LTR and a
reverse primer binding to an adaptor sequence (Figure 1B). The frag-
ments containing the provirus 30 LTR were further enriched by a sec-
ond PCR, using a nested forward primer that was placed internal to
the first forward primer. Of note, the size of the PCR product would
still be unique to each infected cell lineage, because although the viral
sequence length is the same in all amplicons, the length of the human
sequence varies according to the restriction site.Clonal Proliferation of HTLV-1-Infected Cells Can Be Assessed
by Agarose Gel Electrophoresis
We extracted genomic DNA from peripheral blood mononuclear
cells (PBMCs) from asymptomatic HTLV-1 carriers (n = 8), ATLL
patients (n = 10) and a healthy individual, and for ATLL case 4,
from a resected lymph node. The genomic DNA was digested with
HpyCH4V and adaptors were ligated to the restriction fragments to
prepare a restriction fragment library containing adaptor sequences.
We ensured that the size of most fragments of the library were <1
kb without size selection (Figure S1). We subsequently performed
semi-nested PCR as described above and analyzed the products by
agarose gel electrophoresis (Figure 2).
Smeared bands were observed in samples derived from asymptomatic
carriers, suggesting that restriction fragments containing a provirus
are present but vary in size. In other words, smeared bands suggestber 2020
Figure 3. Clonal Structure of ATLL Patients Analyzed by Amplicon Deep
Sequencing Based on HTLV-1 Integration Sites
(A) Sequencing data analysis of amplicons that contain the 30 LTR of a provirus,
human sequences, and the adaptor sequence. Both provirus and adaptor se-
quences were trimmed and only human sequences were clustered. (B) The pro-
portions of UISs in ATLL patients. Restriction fragments containing both the 30 LTR
of a provirus and human sequences were amplified as depicted in Figure 1B and
subjected to deep sequencing. All samples were PBMCs except for case 4, which
was an involved lymph node.
www.moleculartherapy.orgthe presence of small amounts of various HTLV-1-infected cells in the
samples. Clear bands were observed in samples from all ATLL pa-
tients. A band indicates a large amount of a specific restriction frag-
ment that contains a provirus; that is, a band represents clonal prolif-Molecular Theeration of an infected cell. A single band was observed in seven
patients (cases 2, 3, 5, 6, 7, 8, and 10), indicating that an infected
cell proliferated clonally to become a monoclonal tumor population.
More than one band was observed in four patients (cases 1, 4, 9, and
11), suggesting that more than one infected cell proliferated clonally
to produce the oligoclonal tumor populations. Thus, the electropho-
resis results addressed the clinically important questions of whether
HTLV-1-infected cells proliferate clonally and, if so, are they mono-
clonal or oligoclonal.
Clonal Structure Constructed by Amplicon Deep Sequencing
We next assessed and quantified the UIS composition of the ATLL
samples to determine the clonal structure of each patient’s malignant
clone(s). We performed deep sequencing of the semi-nested PCR
products to determine UISs in individual infected cells and quantified
the fraction they comprised. We acquired 100,000–200,000 reads in
depth, determined the UISs, clustered them, and constructed clone
structures therefrom (Figure 3A). Seven patients (cases 2, 3, 5, 6, 7,
8, and 10) had only one dominant clone, whereas in four patients
(cases 1, 4, 9, and 11), more than one clone was found (Figure 3B).
These results were consistent with the appearance of the semi-nested
PCR products after electrophoresis (Figure 2).
Quantification of Individual Dominant Clones by Clone-Specific
digital PCR
To validate the clonal structure estimated by amplicon deep
sequencing, we next measured the proviral load (PVL) of dominant
clones, as well as that of total infected cells. We developed clone-spe-
cific digital PCR (CS-dPCR) to quantify individual dominant clones
using a forward primer binding within the provirus 30 LTR, a TaqMan
probe binding the 30 LTR downstream of that, and a reverse primer
binding to the UIS (Figure 4A). We also designed another TaqMan
probe and primer set within the HTLV-1 tax gene to target provirus
alone and enable quantification of the PVL of total infected cells (Fig-
ure 4A). We performed dPCR using the same genomic DNA tem-
plates used in amplicon deep sequencing and quantified the copy
number of dominant clones, as well as that of total infected cells.
The PVL was determined as described in the Materials and Methods
and indicates the proportion of HTLV-1-infected cells in a sample
unless, as may occur rarely, more than one provirus is present in an
infected cell.
We quantified the dominant clone, shown in blue in Figure 3B, in pa-
tients who contained only one dominant clone (cases 2, 3, 5, 6, 7, 8,
and 10). In each case, the clone represented the majority of the in-
fected cells (Figure 4B). Two clones, which are shown in blue and
red in Figure 3B, were quantified in those cases with two major clones
(cases 1, 4, and 11). The majority of infected cells consisted of the two
clones (Figure 4B), although the ratios of the two clones were not al-
ways consistent with those estimated by deep sequencing. Three
clones, which are shown in blue, red, and gray in Figure 3B, were
quantified in case 9. However, none of them were dominant (Fig-
ure 4B). These results demonstrated that the clonal structure deter-
mined by amplicon deep sequencing was not always accurate butrapy: Methods & Clinical Development Vol. 19 December 2020 469
Figure 4. Quantification of Patient-Specific Tumor Clones by CS-dPCR
(A) Design of TaqMan probes and primers to quantify specific clones and total in-
fected cells. The reverse primer binding sites were placed in UISs to quantify specific
clones. Oligonucleotide sequences are provided in Table S2. (B) The PVLs of
specific clones, as well as that of total infected cells, were measured by dPCR. The
samples were the same as in Figure 3B. The blue and red clones of each patient are
identical to those shown in Figure 3B. Subtraction of blue and red clones from total
infected cells are shown as other infected cells in gray.
Molecular Therapy: Methods & Clinical Developmentenabled the UISs of dominant clones in 10 out of 11 patients to be
identified.
Clone Dynamics in Response to Treatments in ATLL Patients
We next applied CS-dPCR to track individual clones in two patients
with two clones (cases 1 and 11) and monitored the response to treat-
ment. We measured the PVL of the two clones, as well as that of total
infected cells in case 1 (Figure 5A). Clone 1 increased during EPOCH
(etoposide, cyclophosphamide, vincristine, doxorubicin, and predni-
sone) chemotherapy and decreased after its completion, whereas
clone 2 decreased during the chemotherapy and increased afterward.
Both clones and other infected cells were almost eliminated from the
peripheral blood after peripheral blood stem cell transplantation
(PBSCT). However, a skin lesion developed 4 months after the
PBSCT. We extracted genomic DNA from the skin lesion, carried
out CS-dPCR, and found that the skin infiltrate was of clone 2 origin.
We tracked three clones in case 11 (Figure 5B). The patient was
treated with mogamulizumab in addition to combination chemo-
therapy. We measured the PVL of the three clones, as well as that
of total infected cells for 2 weeks. After chemotherapy with AMP
(doxorubicin, ranimustine, and prednisone), clone 2 decreased but
clone 1 increased suggesting that this therapy was more effective
against clone 2 than clone 1. Both clones decreased following moga-
mulizumab, and clone 1 then further decreased after therapy with
VECP (vindesine, etoposide, carboplatin, and prednisone). Little
change was observed in clone 3 after each therapy. The PVL of total
infected cells decreased after each of the three therapies.470 Molecular Therapy: Methods & Clinical Development Vol. 19 DecemThe clonal structure thus changed markedly during treatment and
CS-dPCR allowed us to assess the progression and resistance of
each clone in response to treatment quantitatively. By contrast, the to-
tal PVL, which is currently used clinically as a measurement of PVL,
does not provide any information about clone dynamics and could,
therefore, lead to misunderstanding of the disease progression and
response to therapy.
DISCUSSION
We have developed a comprehensive methodology for clonal assess-
ment of HTLV-1-infected cells (Figure S2). From a clinical point of
view, our methodology has substantial advantages over other
methods. First, it allows us to address whether and, if so, how
many, HTLV-1-infected cells proliferate clonally using PCR followed
by agarose gel electrophoresis without the need for sequencing.
Southern blot hybridization is currently used for this purpose in clin-
ical laboratories, but requires a lot of genomic DNA, time, and labor;
our method overcomes these disadvantages and could potentially
replace it. Second, UISs of dominant clones can be identified by
deep sequencing of PCR products followed by clustering sequencing
reads using user-friendly interfaces without any bioinformatics anal-
ysis. The analysis of sequencing data is straightforward and less
complicated than previous methods, which rely on sonicated frag-
ment libraries being amplified and sequenced. Such methods require
computational analysis to reconstruct the clone structure because
sequencing reads are different in size even if they contain a common
integration site. Sequencing data should be interpreted by computa-
tional methods that analyze UISs to identify dominant clones.8–10
The pipelines leading to the analysis of sequencing data are often
complicated and unstandardized,4 whereas our use of a restriction
enzyme instead of sonication for DNA fragmentation avoids these
problems. Third, once UISs of dominant clones are identified by am-
plicon deep sequencing, CS-dPCR can be designed to enable unique
and specific clones to be quantified and tracked per patient. Currently,
there is no means to quantify patient-specific clones in a clinical
setting.We developed CS-dPCR to quantify and track patient-specific
clones and to provide a clinically useful tool for clonal assessment of
ATLL. Adoption of our methods by clinical laboratories is feasible
and could contribute toward optimal tailored care for individual pa-
tients with ATLL. The present methodology is distinct from that of a
recently published method that amplifies HTLV-1 integration sites
using linear amplification-mediated PCR.15 This method estimates
clonality using sanger sequencing but can neither determine clonal
proliferation of infected cells nor estimate clonality by using electro-
phoresis prior to sequencing. Moreover, it is not designed to track in-
dividual tumor clones.
The total PVL was over 100% in two patients (cases 3 and 4; Fig-
ure 4B). There are two possible explanations for this. One is that a
provirus has integrated into more than one genomic region in an in-
fected cell. If an infected cell that harbors two distinct UISs prolifer-
ates clonally and leads to development of monoclonal tumor popula-
tion, two abundant UISs should be identified at the same frequency
because every tumor cell contains the twoUISs.While this is clinicallyber 2020
Figure 5. Clonal Tracking in ATLL Patients Who Had Two Abundant Clones
The PVLs of patient-specific clones, as well as that of total infected cells among
CD4+ T cells were tracked by dPCR in ATLL cases 1 and 11. The blue and red
clones of each patient are identical to those shown in Figures 3B and 4B. Sub-
traction of tracked clones from total infected cells are shown as other infected cells
in gray. (A) The PVLs of two clones, as well as that of total infected cells, were
tracked during EPOCH chemotherapy and after PBSCT in case 1. All samples were
peripheral blood CD4+ T cells, except for the last, which was a skin lesion. (B) The
PVLs of three clones as well as that of total infected cells were tracked in case 11,
who received mogamulizumab in addition to the VCAP-AMP-VECP regimen, which
included vincristine, cyclophosphamide, doxorubicin, prednisone, ranimustine,
vindesine, etoposide, and carboplatin.
www.moleculartherapy.orguncommon,11 it is conceivable in case 4, as two abundant UISs were
identified at the same frequency (Figure 4B). The other possible
explanation is amplification of a provirus in an infected cell. Ampli-
fication of genomic regions often occurs in cancer, including ATLL.5
If a provirus is amplified in an infected cell during clonal proliferation
of the cell, more than one provirus is present per cell and thus the PVL
can be over 100%. This could explain the finding in case 3 as only one
dominant UIS was identified (Figure 4B).
We found three limitations in themethodology. First, the absence and
presence of HTLV-1 provirus were barely distinguishable by electro-
phoresis; a faint smeared band was observed even in the PBMCs
derived from the healthy individual (Figure 2). The nonspecificMolecular Theamplification could be due to reverse primer binding because every
template fragment contains the adaptor sequence to which they
bind. The reverse primers that are extended from every fragment
could lead to nonspecific amplification if forward primers do not
bind to a provirus. Second, distinct bands may be detectable by elec-
trophoresis even in asymptomatic carriers when the total PVL is very
low; a few faint bands were visible in the sample from the asymptom-
atic carrier 7 whose PVL was less than 0.5% (Figure 2; Table S1).
When the size of the infected cell population is very small, clonal
composition tends to be less heterogeneous and therefore the inten-
sity of several bands may be increased. Third, we failed to identify
UISs of dominant clones in case 9. This is probably due to the failure
to amplify restriction fragments containing UISs of the dominant
clones. The UISs of dominant clones should be identified by amplicon
deep sequencing as long as restriction fragments that contain the UISs
of the dominant clones are amplified by PCR. However, if the 30 end
of the provirus of the dominant clone is truncated, or if the restriction
fragment is too long to be amplified by PCR,16 restriction fragments
containing UISs cannot be amplified. The truncation of the 30 end of a
provirus in ATLL cells is uncommon but could occur in rare cases.14
Our method, like some others, cannot identify UISs of dominant
clones in such cases.
MATERIALS AND METHODS
Clinical Samples
Peripheral blood samples were taken from a healthy individual who
was not infected with HTLV-1, asymptomatic individuals who were
infected with HTLV-1 (asymptomatic carriers; n = 8), and ATLL pa-
tients (n = 10). For ATLL case 4 with lymphomatous disease, an
involved inguinal lymph node sample was used rather than a blood
sample, and for ATLL case 1, an involved skin tissue was used in addi-
tion to a blood sample. Clinical and demographic characteristics of
the asymptomatic carriers and ATLL patients are provided in Table
S1. All samples were collected at Nagasaki University Hospital. The
study was approved by the ethics committee of Nagasaki University
Hospital. PBMCs and CD4+ T cells were separated from whole blood
using Lymphoprep (Axis-Shield Density Gradient Media), and an
EasySep Direct Human CD4+ T Cell Isolation Kit (STEMCELL Tech-
nologies), respectively.
Preparation of Restriction Fragment Library
Genomic DNA was extracted from PBMCs, CD4+ T cells, and the
lymph node and skin samples using a QIAamp DNA Blood Mini
Kit (QIAGEN). Genomic DNA (1 mg) was fragmented using the re-
striction enzyme HpyCH4V (New England Biolabs) at 37C for 1
h. The enzyme was subsequently inactivated at 65C for 20min. NEB-
Next adaptors were ligated to the fragments using a NEBNext Ultra
DNA Library Prep Kit for Illumina (New England Biolabs) and NEB-
Next Mulitiplex Oligos for Illumina (New England Biolabs). NEB-
Next End Prep, Adaptor Ligation, and Cleanup without Size Selection
steps were performed according to the manufacturer’s protocol. The
“PCR Enrichment of Adaptor Ligated DNA” step of the protocol was
not performed; instead, semi-nested PCR was carried out as described
below.rapy: Methods & Clinical Development Vol. 19 December 2020 471
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The first round PCR was performed in 50 mL reaction mixture con-
taining 5 mL adaptor ligated DNA fragments, 25 mL NEBNext Q5
Hot Start HiFi PCR Master Mix, and 0.5 mM forward and reverse
primers. The product of the first amplification reaction was diluted
in water (1:100) and used as the template for the second PCR. The sec-
ond round of PCR was performed in 50 mL reaction mixture contain-
ing 5 mL diluted template, 25 mL NEBNext Q5 Hot Start HiFi PCR
Master Mix, and 0.5 mM forward and reverse primers. The cycling
conditions for both first and second round PCRs were 98C for 30
s, 35 cycles of 98C for 10 s, and 72C for 75 s, followed by 72C
for 2 min and an infinite hold at 4C. The primer sequences are pro-
vided in Table S2.
Agarose Gel Electrophoresis
The semi-nested PCR product was mixed with loading buffer (Wako)
and loaded into wells of a 2% agarose gel alongside a 100 bp DNA
Ladder RTU (Gene DireX) size marker. After electrophoresis, the
agarose gel was stained with ethidium bromide and DNA revealed
with UV light.
Amplicon Deep Sequencing
The semi-nested PCR products were purified using Agencourt AM-
Pure XP (Beckman Coulter) according to the manufacturer’s instruc-
tions. The purified amplicons were quantified using a Bioanalyzer
High Sensitivity DNA Analysis (Agilent) system, diluted with water
to 18 pM, and mixed with Ion PGM Hi-Q View Ion Sphere Particles
(ISPs) using an Ion PGM Hi-Q View OT2 Kit (Thermo Fisher Scien-
tific) in the Ion OneTouch 2 System (Thermo Fisher Scientific). The
template-positive Ion PGMHi-QView ISPs were prepared according
to the Ion PGM Hi-Q View OT2 Kit - 400 protocol and sequenced
using an Ion PGMHi-Q View Sequencing Kit (Thermo Fisher Scien-
tific) and Ion 318 Chip Kit v2 BC (Thermo Fisher Scientific).
Sequencing data were analyzed using CLC Genomics Workbench
(CLC Bio). The HTLV-1 30 LTR and the adaptor sequence were
trimmed from the amplicon sequence and UISs were clustered by
operational taxonomical unit (OTU) clustering analysis and the
UISs of dominant clones were identified. The amplicons generated
from the HTLV-1 50 LTR that contained only viral sequences were
removed before clustering analysis.
Digital PCR
Digital PCR (dPCR) was performed using a QuantStudio 3D Digital
PCR System (Applied Biosystems) in 14.5 mL reaction mixture con-
taining 2 ng/mL genomic DNA template, 1 QuantStudio 3D Digital
PCR Master Mix v2, 0.45 mM forward and reverse primers, 0.125 mM
TaqMan probe, and 1 TaqMan copy number reference assay RNase
P (Applied Biosystems). Sequences of probes and primers are shown
in Table S2. The reporter dyes of the TaqMan probes hybridizing to
provirus and RNase P were FAM and VIC, respectively. The cycling
conditions were 96C for 10 min, 39 cycles of 98C for 30 s, and 60C
for 2 min, 60C for 2 min, and infinite hold at 10C. The PVL was
calculated as: PVL = 100  (provirus copy number  2)/RNase P
copy number.472 Molecular Therapy: Methods & Clinical Development Vol. 19 DecemSUPPLEMENTAL INFORMATION
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